NO.1 Õþ¸®¶¯Ì¬
? ¹ú¼ÒÎÀ½¡Î¯¡¢²ÆÕþ²¿¡¢ÖÐÒ½Ò©¹ÜÀí¾Ö£ºÁªºÏÓ¡·¢¡¶¹ØÓÚ×öºÃ2020Äê»ù±¾¹«¹²ÎÀÉú·þÎñÏîÄ¿¹¤×÷µÄ֪ͨ¡·
½üÈÕ£¬¹ú¼ÒÎÀÉú½¡¿µÎ¯¡¢²ÆÕþ²¿¡¢ÖÐÒ½Ò©¹ÜÀí¾ÖÁªºÏÓ¡·¢¡¶¹ØÓÚ×öºÃ2020Äê»ù±¾¹«¹²ÎÀÉú·þÎñÏîÄ¿¹¤×÷µÄ֪ͨ¡·¡£Í¨ÖªÒªÇó£ºÒ»ÊÇÃ÷È·×ʽðºÍÖ÷Òª¹¤×÷ÈÎÎñ¡£¶þÊÇÇÐʵ×öºÃ³£Ì¬»¯ÒßÇé·À¿Ø¡£ÈýÊÇÍÆ½ø¾ÓÃñµç×Ó½¡¿µµµ°¸ÎñʵӦÓá£ËÄÊÇÉ»ù²ãÂý²¡¹ÜÀíÒ½·ÀÈںϡ£¡¶Í¨Öª¡·Í¬Ê±Ç¿µ÷£¬½øÒ»²½ÍêÉÆ»ù±¾¹«¹²ÎÀÉú·þÎñÏîÄ¿¹ÜÀíÔËÐлúÖÆ£¬¼ÓÇ¿ºÍÓÅ»¯ÏîÄ¿¼¨Ð§ÆÀ¼Û£¬ÓÐЧ¼õÇá»ù²ã¹¤×÷¸ºµ££¬¼ÌÐø×öºÃÏîÄ¿Ðû´«¹¤×÷£¬ÔÚÐÂÐÎÊÆÏ³ÖÐøÇ¿»¯»ù±¾¹«¹²ÎÀÉúÏîĿʵʩµÄ¿ÆÑ§ÐÔºÍÓÐЧÐÔ£¬²»¶ÏÌáÉý³ÇÏç¾ÓÃñ¶Ô»ù±¾¹«¹²ÎÀÉú·þÎñÏîÄ¿µÄÖªÏþÂÊ¡¢¸ÐÊܶȣ¬ÍƽøÌá¸ßÏîÄ¿·þÎñ¸²¸ÇÂÊ¡¢ÂúÒâ¶È¡££¨¹ú¼ÒÎÀ½¡Î¯£©
? ¹ú¼ÒÎÀ½¡Î¯£ºÓ¡·¢¡¶¸ÎÔà¡¢ÉöÔà¡¢ÐÄÔà¡¢·ÎÔàÒÆÖ²¼¼ÊõÒ½ÁÆÖÊÁ¿¿ØÖÆÖ¸±ê£¨2020Äê°æ£©µÄ֪ͨ¡·
½üÈÕ£¬¹ú¼ÒÎÀ½¡Î¯ÔÚǰÆÚ¹¤×÷µÄ»ù´¡ÉÏ£¬½áºÏ¡¶¹ú¼ÒÒ½ÁÆ·þÎñÓëÖÊÁ¿°²È«±¨¸æ¡·¼à²âÇé¿ö£¬×éÖ¯Ïà¹Ø×¨Òµ¹ú¼ÒÖÊ¿ØÖÐÐÄÖÆ¶¨ÁËһϵÁÐÖÊ¿ØÖ¸±ê£¬Ó¡·¢¡¶¸ÎÔà¡¢ÉöÔà¡¢ÐÄÔà¡¢·ÎÔàÒÆÖ²¼¼ÊõÒ½ÁÆÖÊÁ¿¿ØÖÆÖ¸±ê£¨2020Äê°æ£©¡·¡£Ö¸±êåàÑ¡ÖÆ¶¨Ö÷ÒªÌåÏÖ¿ÆÑ§ÐÔ¡¢¹æ·¶ÐԺͿɲÙ×÷ÐÔ¡££¨Ò½ÕþÒ½¹Ü¾Ö£©
? ¹ú¼ÒÒ½±£¾Ö£ºÓ¡·¢¡¶Ò½ÁƱ£Õϼ²²¡Õï¶ÏÏà¹Ø·Ö×飨CHS-DRG£©Ï¸·Ö×é·½°¸£¨1.0°æ£©¡·
½üÈÕ£¬°´ÕÕ¼²²¡Õï¶ÏÏà¹Ø·Ö×飨DRG£©¸¶·Ñ¹ú¼ÒÊԵ㹤×÷°²ÅÅ£¬ÎªÂäʵÊԵ㹤×÷¡°Èý²½×ß¡±Ä¿±ê£¬Ö¸µ¼¸÷µØ¹æ·¶DRG·Ö×鹤×÷£¬¹ú¼ÒÒ½±£¾Ö×éÖ¯ÖÆ¶¨ÁË¡¶Ò½ÁƱ£Õϼ²²¡Õï¶ÏÏà¹Ø·Ö×飨CHS-DRG£©Ï¸·Ö×é·½°¸£¨1.0°æ£©¡·¡£CHS-DRGϸ·Ö×éÊǶԡ¶¹ú¼ÒÒ½ÁƱ£ÕÏDRG£¨CHS-DRG£©·Ö×é·½°¸¡·376×éºËÐÄDRG£¨ADRG£©µÄ½øÒ»²½Ï¸»¯£¬ÊÇDRG¸¶·ÑµÄ»ù±¾µ¥Ôª£¬¹²618×é¡£¸÷ÊÔµã³ÇÊÐÒª²Î¿¼CHS-DRGϸ·Ö×éµÄ·Ö×é½á¹û¡¢ºÏ²¢Ö¢²¢·¢Ö¢/ÑÏÖØºÏ²¢Ö¢²¢·¢Ö¢±í£¨CC&MCC±í£©¡¢·Ö×鹿Ôò¡¢ÃüÃû¸ñʽµÈ£¬Öƶ¨±¾µØµÄDRGϸ·Ö×é¡£¸ù¾Ýʵ¼ÊÇé¿ö£¬ÊÔµã³ÇÊÐÒ²¿ÉÖ±½ÓʹÓÃCHS-DRGϸ·Ö×鿪չ±¾µØµÄDRG¸¶·Ñ¹ú¼ÒÊԵ㹤×÷¡££¨Ò½±£¾ÖÍøÕ¾£©
? ¹ú¼ÒÒ½±£¾Ö£º¸÷µØÓ¦°´³ÌÐò½«ºËËá¼ì²âÏîÄ¿ÄÉÈëÒ½±£
6ÔÂ19ÈÕ£¬¹ú¼ÒÒ½±£¾Ö¾Í×öºÃйڲ¡¶¾¼ì²âµÄ¹ÒÍø²É¹º¡¢¼Û¸ñ¹ÜÀíºÍÒ½±£Ö§¸¶¹¤×÷·¢²¼Í¨Öª£¬Ã÷È·¸÷µØÒªÔÚ×ۺϿ¼ÂÇÐÂÐ͹Ú×´²¡¶¾·ÎÑ×·À¿Ø¹¤×÷ÐèÒª¡¢±¾µØÇøÒ½±£»ù½ðÖ§¸¶ÄÜÁ¦µÈÒòËØµÄ»ù´¡ÉÏ£¬°´³ÌÐò½«Õë¶Ôйڲ¡¶¾¿ªÕ¹µÄºËËá¡¢¿¹Ìå¼ì²âÏîÄ¿ºÍÏà¹ØºÄ²ÄÄÉÈëÊ¡¼¶Ò½±£ÕïÁÆÏîĿĿ¼£¬²¢Í¬²½È·¶¨Ö§¸¶Ìõ¼þ¡££¨¹âÃ÷ÈÕ±¨£©
? ³¤Èý½Ç£º³¤Èý½ÇÒ½±£Ò»Ì廯ÉîÈëÍÆ½ø£¬ÈýʡһÊÐÃÅÕï·ÑÓÿçʡֱ½Ó½áËãʵÏÖÈ«¸²¸Ç
6ÔÂ19ÈÕ£¬³¤Èý½ÇµØÇøÒ½±£Ò»Ì廯¹¤×÷×ù̸»áÔÚÕ㽺þÖÝÕÙ¿ª¡£»áÒé¶Ô2020ÄêÒ½±£Ò»Ì廯Ö÷Òª¹¤×÷Ä¿±êºÍÈÎÎñ½øÐÐÁËÈ«Ãæ²¿Êð¡£½ØÖÁ2020Äê5Ôµף¬½áË㷶ΧÒѸ²¸Ç³¤Èý½ÇÈ«²¿41¸ö³ÇÊУ¬¸²¸Ç5600Óà¼ÒÒ½ÁÆ»ú¹¹£¬ÈýʡһÊоÓÃñÔÚ41¸ö³ÇÊеÄÖ÷ÒªÒ½ÁÆ»ú¹¹ÃÅÕï»òסԺ¾ù¿É³Ö¿¨¾ÍÒ½¡¢ÊµÊ±½áËã¡£ÁíÍ⣬ÈýʡһÊÐÒ½±£²¿ÃŽ«Ö÷Òª×öºÃÒÔϹ¤×÷£ºÈ«Á¦±£ÕÏÒßÇéÒ½ÁƾÈÖι¤×÷¡¢¿ªÕ¹Çà¼ÎÎâÒ½±£Ò»Ì廯ʾ·¶Çø½¨Éè¡¢×öºÃËÕÕãÍîÈýÊ¡ÒìµØÃÅÕﻥÁª»¥Í¨ÒÔ¼°¿ªÕ¹¡°»¥ÁªÍø+Ò½±£¡±ÔÚÏß½áËãÊԵ㡣£¨Õã½·¢²¼£©
? ÉϺ£ÊУºÉϺ£Ò½ÁÆ·ÑÓñ¨ÏúÂÊÏÈʵÏÖ¡°Ò»¼þÊÂÒ»´Î°ì¡±
½üÈÕ£¬Ò½ÁƷѱ¨Ïú¡°Ò»¼þÊ¡±ÔÚ¡°Ò»ÍøÍ¨°ì¡±×ÜÃÅ»§¡°Ò»¼þÊÂÒ»´Î°ì¡±×¨À¸Õýʽ·¢²¼¡£Ò½ÁƷѱ¨Ïú¡°Ò»¼þÊ¡±ÉÏÏߺó£¬ÎÞÂÛÊÇʹÓá°Ò»ÍøÍ¨°ì¡±ÍøÒ³°æµÄÏßÉÏÇþµÀ£¬»¹ÊÇͨ¹ýÉçÇøÊÂÎñÊÜÀíÖÐÐĵÈÏßÏ´°¿Ú°ìÀí£¬ÉêÇëÈËÖ»ÐèÒ»´ÎÉêÇë¡¢Ò»´ÎÌî±í£¬¾ÍÄÜͬ²½Íê³ÉÒ½ÁƷѱ¨Ïú¡¢Ò½ÁƾÈÖú¶ÔÏó¾»ù±¾Ò½±£·ÑÓñ¨ÏúºóµÄ¾ÈÖú½ð¸ø¸¶µÈÏà¹Ø°ìÀíÊÂÏîµÄÒµÎñÊÜÀí»·½Ú¡££¨½â·ÅÈÕ±¨£©
?ÉϺ£ÊУºÉϺ£¼ÓÇ¿¹«ÎÀÌåϵ½¨ÉèÈýÄêÐж¯¼Æ»®·¢²¼
6ÔÂ19ÈÕ£¬ÉϺ£ÊÐÈËÃñÕþ¸®°ì¹«Ìü¹ØÓÚת·¢ÊÐÎÀÉú½¡¿µÎ¯µÈËIJ¿ÃÅÖÆ¶©µÄ¡¶ÉϺ£ÊмÓÇ¿¹«¹²ÎÀÉúÌåϵ½¨ÉèÈýÄêÐж¯¼Æ»®£¨2020-2022Ä꣩¡·µÄָ֪ͨ³ö£¬µ½2022Ä꣬±¾Êй¹½¨ÁéÃô¸ßЧ¡¢¿ÆÑ§¾«×¼¡¢Áª·ÀÁª¿Ø¡¢Èº·ÀȺÖεĹ«¹²ÎÀÉúʼþÓ¦¼±´¦ÖÃÌåϵ£»½¡È«Ö°ÔðÃ÷Îú¡¢ÏνÓÓÐÐò¡¢Ò½·ÀÈںϡ¢ÖÐÎ÷Ò½²¢ÖØ¡¢±£ÕÏÓÐÁ¦µÄ¹«¹²ÎÀÉú×ۺϷþÎñ»úÖÆ£»ÍêÉÆÈ«ÈËȺ¡¢È«ÖÜÆÚ¡¢È«Á÷³ÌµÄ½¡¿µ·þÎñºÍ¹ÜÀíģʽ£¬´Ù½ø¹«ÖÚ½¡¿µËØÑøºÍ½¡¿µË®Æ½ÕûÌåÌáÉý¡££¨ÉϺ£ÊÐÕþ¸®¹ÙÍø£©
? ÉϺ£ÊУºÈ«¹úÊ׸ö¡°Ó¤Ó×¶ùÕÕ»¤·þÎñÑÐÐÞ»ùµØ¡±Âä»§ÉϺ£
½üÈÕ£¬Ó¤Ó×¶ù¿ÆÑ§Óý¶ù¸ß·åÂÛ̳ÔÚÖи£»áÉÙÄ깬¾ÙÐС£Óɹú¼ÒÎÀ½¡Î¯ÊÚÓèµÄÈ«¹úÊ׸ö¡°Ó¤Ó×¶ùÕÕ»¤·þÎñÑÐÐÞ»ùµØ¡±Âä»§ÉϺ£¡£Î´À´£¬Öи£»áÍжùËù½«ÔÚÍÐÓýÈËÔ±Åàѵ¿Î³Ì¿ª·¢¡¢¼ÒÍ¥¿ÆÑ§½ÌÑøÖ¸µ¼¡¢²»Í¬Ä£Ê½µÄÓ¤Ó×¶ùÕÕ»¤·þÎñ»ú¹¹¿Î³ÌÉèÖÃÓëʵ¼ùµÈ·½Ã棬ÏòÈ«¹úÌṩ¾Ñéʾ·¶ºÍ¿ÉÍÆ¹ãģʽ¡££¨½â·ÅÈÕ±¨£©
? ½ËÕÊ¡£ºÊ¡Ó¦¼±¹ÜÀíÌüÓëÊ¡ÎÀ½¡Î¯Ç©¶©ºÏ×÷¿ò¼ÜÐÒé
6ÔÂ19ÈÕ£¬½ËÕʡӦ¼±¹ÜÀíÌüÓë½ËÕÊ¡ÎÀÉú½¡¿µÎ¯¾ÙÐкÏ×÷ÐÒéÇ©¶©ÒÇʽ£¬½¨Á¢Ç¿»¯Í»·¢Ê¼þ½ô¼±Ò½Ñ§¾ÈÔ®ºÍʹÊÔÖº¦Ò½ÁƾÈÖεÄÉî¶ÈºÏ×÷»úÖÆ¡£½ËÕʡӦ¼±¹ÜÀíÌüºÍ½ËÕÊ¡ÎÀ½¡Î¯Ö÷Òª¸ºÔðͬ־·Ö±ð´ú±íË«·½Ç©Ô¼¡£ÐÒéÃ÷È·£¬Ë«·½½«Ç¿»¯ÐÅÏ¢¹²Ïí»úÖÆ¡¢ÍêÉÆÒ½ÁƾÈÖλúÖÆ¡¢¼ÓÇ¿³£Ì¬»¯Áª¶¯»úÖÆ¡¢ÓÅ»¯ÁªºÏÅàѵ»úÖÆ¡¢ÍƽøÁªºÏÑÝÁ·»úÖÆ¡¢ÂäʵӦ¼±¿ÆÆÕÐû´«»úÖÆ¡¢½¡È«Ð×÷¹²½¨»úÖÆµÈÆßÏî»úÖÆ£¬²¢³ÉÁ¢Áª¶¯¹¤×÷С×鿪չÈÕ³£¹¤×÷¡££¨Ð»ªÈÕ±¨£©
? ½ËÕÊ¡£º¡¶ÄϾ©ÊÐÑøÀÏ·þÎñÌõÀý¡·7ÔÂ1ÈÕÕýʽʵʩ
½üÈÕ£¬¾ÝÄϾ©ÊÐÈË´ó³£Î¯»áÕÙ¿ªµÄÐÂÎÅ·¢²¼»áÏûÏ¢£¬¡¶ÄϾ©ÊÐÑøÀÏ·þÎñÌõÀý¡·½«ÓÚ7ÔÂ1ÈÕÕýʽʵʩ¡£¾ÝÁ˽⡶ÌõÀý¡·¹²9ÕÂ74Ìõ£¬°üÀ¨Á˾Ӽҡ¢ÉçÇø¡¢»ú¹¹ÑøÀÏ¡¢Ò½Ñø½áºÏ¡¢È˲ŶÓÎ齨Éè¡¢·ö³Ö±£ÕϵÈÄÚÈÝ¡££¨ÏÖ´ú¿ì±¨£©
? Õã½Ê¡£ºÕã½Íƽø»¼Õß¾ÍÒ½ÌåÑé´óÌáÉý
½üÈÕ£¬Õã½Ê¡Î¯¸Ä¸ï°ì£¨Ê¡Åܸİ죩¡¢Ê¡ÎÀÉú½¡¿µÎ¯ÁªºÏÓ¡·¢¡¶Õã½Ê¡ÉҽÁÆÎÀÉú·þÎñÁìÓò¡°×î¶àÅÜÒ»´Î¡±¸Ä¸ïÍÆ½ø¾ÍÒ½ÌåÑé´óÌáÉýʵʩ·½°¸¡·£¬¹«²¼Öص㹤×÷ÈÎÎñ£¬ÒªÇóÈ«ÃæÌáÉý»¼Õß¾ÍÒ½ÌåÑé¡£µ½2020ÄêÄêµ×£¬ËùÓлù²ãÒ½ÁÆÎÀÉú»ú¹¹ºÅÔ´ÄÉÈëÕã½Ê¡½¡¿µµ¼º½Æ½Ì¨£»¶þ¼¶ÒÔÉÏÒ½ÁÆ»ú¹¹È«Ã濪չ·Öʱ¶Î¾«×¼Ô¤Ô¼¡££¨½¡¿µ±¨£©
? Õã½Ê¡£ºº¼Öݳǫ̈¡¶º¼Öݽ¡¿µÂ뿪·¢ÔËÐй淶¹ÜÀí°ì·¨¡·
6ÔÂ15ÈÕÆð£¬º¼ÖÝ¿ªÊ¼Ê©ÐС¶º¼Öݽ¡¿µÂ뿪·¢ÔËÐй淶¹ÜÀí°ì·¨¡·¡£°ì·¨¹²ÓÐ17ÌõÄÚÈÝ£¬Ö÷ÒªÌåÏÖÁ˶Խ¡¿µÂëʹÓÃÕ߸öÈËÐÅÏ¢µÄ±£»¤¡£°ì·¨ÒªÇ󣺲»µÃÊÕ¼¯Ó뽡¿µÂë·þÎñÎ޹صĸöÈËÐÅÏ¢£¬Î¥·´¹æ¶¨ÒªÒÀ·¨³Ðµ£ÃñÊ¡¢ÐÐÕþÔðÈΣ¬¹¹³É·¸×ïµÄÒÀ·¨×·¾¿ÐÌÊÂÔðÈΡ££¨¶¼Êп챨£©
? Õã½Ê¡£ºÈð°²Ê×´´¡°ËÍÒ©ÈëÆó+Íø¶©µêËÍ
½üÈÕ£¬Èð°²ÊÐÊг¡¼à¹Ü¾ÖȫʡÊ×´´¡°ËÍÒ©ÈëÆó±ãÃñ·þÎñµã½¨É衱±ãÃñ·þÎñģʽ£¬¿ªÕ¹ËÍÒ©ÈëÆó±ãÃñ·þÎñµã½¨É裬ÈÃÆóÒµÔ±¹¤×ã²»³ö¡°Æó¡±¾ÍÄܹºÂòµ½ËùÐèҩе£¬°ïÖúÆóÒµÔÚÒßÇé±³¾°ÏÂ×öºÃÈËÔ±¹ÜÀí¹¤×÷¡££¨ÎÂÖÝÈÕ±¨£©
? °²»ÕÊ¡£º°²»ÕÊ¡Íê³Éйڲ¡¶¾Ïà¹Ø¼ì²âÊÔ¼ÁÊ¡¼¶¼¯Öвɹº
Ϊ±£Õϰ²»ÕÊ¡ÐÂÐ͹Ú×´²¡¶¾Ïà¹Ø¼ì²âÊÔ¼ÁµÄÕý³£¹©Ó¦ºÍʹÓ㬴ٽøÏà¹Ø¼ì²âÊÔ¼Á¼Û¸ñ»Ø¹éºÏÀíˮƽ£¬¼õÉÙÒ½±£»ù½ðÖ§³öºÍ½µµÍÈËÃñȺÖÚ¸ºµ££¬°²»ÕʡҽÁƱ£ÕϾֲÉÈ¡¡°ËļÛÁª¶¯·¨¡±£¬»ý¼«¿ªÕ¹ÐÂÐ͹Ú×´²¡¶¾Ïà¹Ø¼ì²âÊÔ¼ÁÊ¡¼¶¼¯Öвɹº¡£´Ó6ÔÂ17ÈÕÆð£¬È«Ê¡¹«Á¢Ò½ÁÆ»ú¹¹¿Éͨ¹ý°²»Õʡҽҩ¼¯ÖвɹºÆ½Ì¨ÓÅÏȲɹºÓÐÏ޼۵ļ¯Öн»Ò×Ŀ¼ÄÚ²úÆ·¡£±¾´ÎºËËá¼ì²âÊÔ¼Á¡¢¿¹Ìå¼ì²âÊÔ¼Á²úÆ·¹ÒÍøÏÞ¼ÛÓëÎÒʡҽÁÆ»ú¹¹Ôʵ¼Ê²É¹º¼ÛÏà±È£¬Æ½¾ù½µ¼Û·ù¶È´ï83%ºÍ67%¡££¨°²»ÕÍø£©
? °²»ÕÊ¡£º°²»Õʡҩ¼à¾ÖÖÆ¶¨³ǫ̈ҩƷÐÐÕþ´¦·£²ÃÁ¿»ù×¼
½üÈÕ£¬°²»Õʡҩ¼à¾ÖÑо¿Öƶ¨ÁËÒ©Æ·ÐÐÕþ´¦·£²ÃÁ¿»ù×¼¡£²ÃÁ¿»ù×¼¹²53Ìõ£¬ÆäÖÐÉæ¼°¡¶Ò©Æ·¹ÜÀí·¨¡·35Ìõ¡¢¡¶ÒßÃç¹ÜÀí·¨¡·14Ìõ¡¢¡¶ÖÐÒ½Ò©·¨¡·1Ìõ¡¢¡¶Ò©Æ·Éú²ú¼à¶½¹ÜÀí°ì·¨¡·1Ìõ£¬ÆäËû¹æ¶¨2Ìõ¡£²ÃÁ¿»ù×¼Õë¶Ô¡°·£¿î¡±¼°¡°Ê®ÄêÖ±ÖÁÖÕÉí½ûÖ¹´ÓÊÂÒ©Æ·Éú²ú¾Óª»î¶¯¡±Á½¸ö´¦·£ÖÖÀ࣬ÖðÏîÃ÷È·¼õÇá´¦·£¡¢´ÓÇá´¦·£¡¢´ÓÖØ´¦·£¡¢Ò»°ã´¦·£µÄ¾ßÌåÇéÐΡ££¨Öа²ÔÚÏߣ©
?°²»ÕÊ¡£º°²»ÕÊ¡Ê×Åú22ËùÈý¼¶Ò½ÁÆ»ú¹¹Ê©ÐÐÏ×ѪÕßÖ±ÃâÓÃѪ·Ñ
½üÈÕ£¬°²»ÕÊ×Åú22ËùÈý¼¶Ò½ÔºÕýʽʵʩÏ×ѪÕß¼°ÆäֱϵÇ×ÊôÁÙ´²ÓÃѪ·ÑÓÃÔÚÒ½ÁÆ»ú¹¹Ö±½Ó¼õÃ⣬ÆäËûÒ½ÔºÓÚ8Ôµ×È«²¿ÊµÊ©£¬×öµ½¡°Ò»¸ö´°¿ÚÊÜÀí¡¢Ò»´ÎÐÔ¸æÖª¡¢Ò»Õ¾Ê½·þÎñ¡±¡££¨Ñë¹ãÍø£©
NO.2 ԺУ¶¯Ì¬
? ÉϺ£½»Í¨´óѧ£ºÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÓë¹ú¼ÒÈÈ´ø²¡Ñо¿ÖÐÐĹ²Í¬³ÉÁ¢ÈÈ´ø²¡ºÍ¼ÄÉú³æ²¡ÕïÁÆÁªÃË
6ÔÂ16ÈÕ£¬¹ú¼ÒÈÈ´ø²¡Ñо¿ÖÐÐÄÓëÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿Ú¹²Í¬³ÉÁ¢¡°ÈÈ´ø²¡ºÍ¼ÄÉú³æ²¡ÕïÁÆÁªÃË¡±¡£ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿Ú¸½ÊôÈð½ðÒ½Ôº¡¢ÈʼÃÒ½Ôº¡¢Ð»ªÒ½Ôº¡¢µÚ¾ÅÈËÃñÒ½Ôº¡¢µÚÒ»ÈËÃñÒ½Ôº¡¢¶ùͯҽѧÖÐÐÄ¡¢ÉϺ£Êо«ÉñÎÀÉúÖÐÐĵÈ7¼ÒÒ½Ôº³ÉΪ¡°ÈÈ´ø²¡ºÍ¼ÄÉú³æ²¡ÕïÁÆÁªÃË¡±Ê×Åú³ÉÔ±¡£ÁªÃ˵ÄÊ×¼ÒÁªºÏÃÅÕï¡°¹ú¼ÒÈÈ´ø²¡Ñо¿ÖÐÐÄ-Èð½ðÒ½ÔºÈÈ´ø²¡Óë¼ÄÉú³æ²¡ÁªºÏÃÅÕҲÔÚ³ÉÁ¢´ó»áÉÏÕýʽ½ÒÅÆ¡££¨ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÍøÕ¾£©
? ÉϺ£½»Í¨´óѧ£ºÒ½taptapµãµã¹ÙÍøÈë¿ÚÓë°²»ÕÀí¹¤´óѧǩÊðÕ½ÂÔºÏ×÷ÐÒé
6ÔÂ20ÈÕÉÏÎ磬ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÓë°²»ÕÀí¹¤´óѧսÂÔºÏ×÷ÐÒéǩԼÒÇʽÔںϷʾÙÐС£°²»ÕÊ¡ÈËÃñÕþ¸®¸±Ê¡³¤Íõ´ä·ï£¬Ê¡Õþи±Ö÷ϯ¡¢½ÌÓýÌüÌü³¤ÀîºÍƽ£¬Ê¡ÈËÃñÕþ¸®¸±ÃØÊ鳤×ó¿¡£¬ÉϺ£½»Í¨´óѧµ³Î¯¸±Êé¼Ç¡¢Ò½taptapµãµã¹ÙÍøÈë¿Úµ³Î¯Êé¼Ç·¶ÏÈȺ£¬°²»ÕÀí¹¤´óѧµ³Î¯Êé¼Ç¹ùÓÀ´æµÈ³öϯ¡£Ç©Ô¼ÒÇʽºó£¬ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÓë°²»ÕÀí¹¤´óѧÕÙ¿ªÍƽøÕ½ÂÔºÏ×÷×ù̸»á¡£Á½Ð£Áìµ¼ÒÔ¼°Ïà¹ØÖ°Äܲ¿ÃŸºÔðÈËÎ§ÈÆÒ½¹¤½»²æÑ§¿Æ´´Ð·¢Õ¹¡¢¿ÆÑÐÏîÄ¿ºÏ×÷¡¢È˲ÅÓëʦ×ʶÓÎéÅàÑø¡¢Ò½ÁÆ·þÎñºÏ×÷¡¢¸É²¿½ÌÓýÅàѵ¡¢¹«¹²ÎÀÉúÓëÖ°Òµ½¡¿µ²úѧÑÐÐͬ·¢Õ¹µÈ»°ÌâÕ¹¿ªÁËÉîÈëÌÖÂۺͽ»Á÷¡££¨ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÍøÕ¾£©
? ÉϺ£½»Í¨´óѧ£º»ù´¡Ò½taptapµãµã¹ÙÍøÈë¿Ú¸ßСÁá¿ÎÌâ×é¡°°ÐÏòµÝËÍ»·æßËØAÖÎÁÆÂÄÔËðÉË¡±Ñо¿³É¹û·¢±í
½üÈÕ£¬ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÒ©ÀíѧÓ뻯ѧÉúÎïѧϵ¸ßСÁáÑо¿Ô±¿ÎÌâ×éÔÚ¡¶ÃÀ¹ú»¯Ñ§Ñ§»á-ÄÉÃס·£¨ACS Nano£©ÔÓÖ¾ÉÏ£¬ÔÚÏß·¢±íÁËÌâΪ¡°Tailored Reconstituted Lipoprotein for Site-Specific and Mitochondria-Targeted Cyclosporine A Delivery to Treat Traumatic Brain Injury¡±µÄÑо¿ÂÛÎÄ¡£Ñо¿ÈËÔ±»ùÓÚÂÄÔËðÉ˲¡Ôî¸ß±í´ï»ùÖʽðÊôµ°°×ø-9£¨MMP-9£©£¬²ÉÓÃøÃô¸Ðϸ°û´©Ä¤ëÄÐÞÊεÄÖ¬µ°°×ÄÉÃ×ÔØÌ彫¶àëÄÒ©Îï»·æßËØA£¨cyclosporine A£¬CsA£©¸ßЧµÝËÍÖÁ²¡Ôîϸ°ûµÄÏßÁ£Ì壬´Ó¶ø¼õÇáÏßÁ£ÌåËðÉË»º½â²¡Ç飬¼«´óÌá¸ßÁËCsAÓÃÓÚÂÄÔËðÉËÖÎÁƵݲȫÐÔºÍÓÐЧÐÔ¡££¨ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÍøÕ¾£©
? ÉϺ£½»Í¨´óѧ£ºÐØ¿ÆÒ½Ôº·½ÎÄÌνÌÊÚÍŶӽ¨Á¢¹ú¼ÊÊ׸öÐØÏÙÖ×ÁöÊõºó¸´·¢Ô¤²âÄ£ÐÍ
½üÈÕ£¬Óɸ½ÊôÐØ¿ÆÒ½Ôº·½ÎÄÌνÌÊÚÁìÏεÄÖйúÐØÏÙÖ×ÁöÐ×÷×éÑо¿ÍŶÓÔÚ¹ú¼Ê·Î°©Ñо¿Ð»áµÄ¹Ù·½ÆÚ¿¯¡¢Ðز¿Ö×ÁöÁìÓò¹ú¼ÊȨÍþѧÊõÔÓÖ¾¡¶ÐØÏÙÖ×ÁöÆÚ¿¯¡·£¨Journal of Thoracic Oncology£©ÉÏ·¢±íÁË×îÐÂÑо¿³É¹û£¬Ìá³ö¡°¹ú¼ÊÊ׸öÐØÏÙÖ×ÁöÊõºó¸´·¢Ô¤²âÄ£ÐÍ¡±£¬Ê¹µÃÐØÏÙÖ×Áö»¼ÕßÊõºóÓÐÁ˸ü¼Ó¾«×¼µÄ·½°¸£¬ÎªÎÒ¹úÒÔ¼°ÊÀ½ç·¶Î§ÄÚÐØÏÙÖ×Áö»¼ÕߵĹÜÀíģʽÌṩÁËÇ¿ÓÐÁ¦µÄÁÙ´²Ö¸µ¼Ó뽨Òé¡££¨ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÍøÕ¾£©
? ÉϺ£½»Í¨´óѧ£ºÉϺ£ÊÐÃâÒßѧÑо¿ËùÍõºêÁÖÍŶÓÔÚImmunity·¢ÎÄ£¬½ÒÊ¾ÒøÐ¼²¡±íƤϸ°ûÖдæÔÚ¡°×ÔÉí¿¹Ô¡±
6 Ô 17 ÈÕ£¬ÉϺ£ÊÐÃâÒßѧÑо¿ËùÍõºêÁÖÍŶÓÔÚ¹ú¼ÊÃâÒßѧ¶¥¼¶ÆÚ¿¯Immunity·¢±íÌâΪ¡°Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in Psoriasis¡±µÄÑо¿ÂÛÎÄ¡£¸ÃÑо¿Ê״νÒʾ£¬×éÖ¯ÌØÒìÐÔϸ°ûµÄ´úÐ»ÖØ±à³ÌËùÒýÆðµÄ´úлÎïÒì³£ÀÛ»ýÊÇÒøÐ¼²¡µÈÂýÐÔÑ×Ö¢ÐÔ¼²²¡·¢Éú·¢Õ¹µÄÖØÒª¡°°ïÐס±£¬±íƤϸ°ûµÄ¡°¶à°·+×ÔÉíºËËá+¶ÌëÄ¡±¸´ºÏÎïÊǼ¤»îƤ·ôÃâÒß·´Ó¦µÄ¡°×ÔÉí¿¹Ô¡±£¬¶ø°ÐÏòµ÷½Ú±íƤϸ°û¾«°±Ëá´úлͨ·µÄÒì³£ÓÐÍû³ÉΪÖÎÁÆÒøÐ¼²¡µÄȫвßÂÔ¡££¨ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÍøÕ¾£©
? ÉϺ£½»Í¨´óѧ£ºÉϺ£½»´óÒ½taptapµãµã¹ÙÍøÈë¿Ú¸½ÊôµÚÒ»ÈËÃñÒ½Ôº·ÅÉä¿Æ·¢±í΢СÖ×ÁöÔçÆÚ¼ì²âÑо¿³É¹û
½üÈÕ£¬ÉϺ£ÊеÚÒ»ÈËÃñÒ½Ôº·ÅÉä¿ÆÍõÖÐÁ츱Ö÷ÈÎҽʦÑо¿ÍŶӣ¬ÁªºÏÃÀ¹ú¼ÓÖÝ´óѧ´÷ά˹·ÖУ×ۺϰ©Ö¢ÖÐÐÄ¡¢ÃÀ¹ú˹̹¸£´óѧҽtaptapµãµã¹ÙÍøÈë¿Ú·ÅÉä¿Æ£¬¹²Í¬Ñз¢³ö¾ßÓоàÀëµ÷¿ØÐÔµÄT1ºÍT2Ë«ÏòµÄ´Å¹²Õñµ÷г£¨TMRET£©ÄÉÃ×̽Õ룬²¢ÎªÆäÁ¿Éí¶¨×öÁ˼ÆËã»úË«¶Ô±ÈÔöÇ¿¼õÓ°¼¼Êõ£¨DESI£©£¬¿É¾«×¼Ì½²âÄÔÄÚÖ±¾¶Ð¡ÓÚ0.8mmµÄ³¬Î¢Ö×Áö¡£½üÈÕ£¬ÕâÒ»Ñо¿·¢±íÓÚ¹ú¼Ê¶¥¼¶Ñ§ÊõNatureÆìÏÂÆÚ¿¯¡¶×ÔÈ»ÄÉÃ׿Ƽ¼¡·£¨Nature Nanotechnology£©¡££¨ÉϺ£½»Í¨´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÍøÕ¾£©
? ¸´µ©´óѧ£º»ù´¡Ò½taptapµãµã¹ÙÍøÈë¿ÚÕÅΰ¾ê¿ÎÌâ×é·¢ÏÖθ°©ÃâÒßÌÓÒÝлúÖÆ
½üÈÕ£¬¸´µ©´óѧ»ù´¡Ò½taptapµãµã¹ÙÍøÈë¿ÚÕÅΰ¾ê½ÌÊÚÍŶÓÀúʱ3Ä꣬¶Ô818Àýθ°©»¼Õß½øÐлعËÐÔ·ÖÎö£¬·¢ÏÖθ°©»¼ÕßÖ×Áö×éÖ¯ÖдæÔÚIL-10ÑôÐÔÖ×ÁöÏà¹Ø¾ÞÊÉϸ°ûÑÇȺ£¬Æä¾ßÓе÷½ÚÃâÒßÒÖÖÆÐÔÖ×Áö΢»·¾³ºÍ´Ù½øÖ×ÁöÃâÒßÌÓÒݵŦÄÜ£¬ÔÚÓÕµ¼¿¹Ö×ÁöÃâÒßÕϰÓ뻯ÁƵֿ¹Öз¢»Ó¹Ø¼ü×÷Ó㬸óɹû¶Ôθ°©»¼ÕߵϝÁÆÑ¡ÔñºÍÃâÒßÖÎÁƾßÓÐÖØÒªÒâÒå¡£Ïà¹ØÑо¿³É¹ûÒÔPoor Clinical Outcomes and Immunoevasive Contexture in IntratumoralIL-10-Producing Macrophages Enriched Gastric Cancer PatientsΪÌâÔÚ×îÐÂÒ»ÆÚ¹ú¼ÊÍâ¿ÆÑ§¶¥¼âÆÚ¿¯¡¶Íâ¿ÆÑ§Äê¼ø¡·£¨Annals of Surgery£©ÔÚÏß·¢±í¡££¨ÖÐÐÂÍøÉϺ££©
? ÉϺ£ÖÐÒ½Ò©´óѧ£ºÁõƽ/¼ÖΰÍŶÓÔÚ¡¶BMC Medicine¡··¢±íÂÛÎÄ¡¶ÖйúÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßѪÇå´úл²úÎïÓëÍíÆÚ¸ÎÏËά»¯µÄÏà¹ØÐÔ¡·
½üÈÕ£¬ÉϺ£ÖÐÒ½Ò©´óѧ½»²æ¿ÆÑ§Ñо¿ÔºÁõƽ/¼ÖΰÍŶÓÔÚ¹ú¼ÊѧÊõÆÚ¿¯¡¶BMC Medicine¡·£¨Ó°ÏìÒò×Ó8.285£©ÉÏ·¢±íÌâĿΪ¡¶ÖйúÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßѪÇå´úл²úÎïÓëÍíÆÚ¸ÎÏËά»¯µÄÏà¹ØÐÔ£¨Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection) ¡·µÄÂÛÎÄ¡£ÎÄÕ½áºÏ×îÐÂÁÙ´²Óë»ù´¡Ñо¿Êý¾Ý£¬¶ÔÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßѪÇåÖдúл²úÎï±êÖ¾ÎïÔÚÕï¶Ï²»Í¬½×¶ÎµÄ¸ÎÏËά»¯¹ý³ÌÖÐÆðµ½µÄ×÷ÓýøÐвûÊö¡££¨ÉϺ£ÖÐÒ½Ò©´óÑ§ÍøÕ¾£©
? ÉϺ£ÖÐÒ½Ò©´óѧ£ºÀîºó¿ªÍŶÓÔÚ¡°³¦µÀ¾ú-µ¨ÖËá´úлÖᡱÓëË¥ÀϵĹØÏµÑо¿ÖÐÈ¡µÃнøÕ¹
½üÈÕ£¬ÉϺ£ÖÐÒ½Ò©´óѧ½»²æ¿ÆÑ§Ñо¿ÔºÀîºó¿ªÍŶÓÔÚ¹ú¼Ê΢ÉúÎïѧרҵÆÚ¿¯Gut Microbes£¨Ò»Çø£¬IF=7.823£©ÔÚÏß·¢±íÁËÌâΪ¡¶³¦µÀ¾úÈºÖØËÜÐÔ±ðÒÀÀµÐԵظÄÉÆÀÏÄêСÊóµÄÌåÄÚÑ×Ö¢Ó뵨ÖËáÎÈ̬ʧºâ¡·£¨Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically£©µÄÑо¿ÂÛÎÄ¡£¸ÃÑо¿±íÃ÷³¦µÀ¾ú-µ¨ÖËá´úлÖáÎÉÂÒ¿ÉÄÜÓëË¥ÀÏÏà¹Ø¼²²¡µÄ·¢Éú·¢Õ¹¸ß¶ÈÏà¹Ø£¬Ò²Îª°ÐÏò³¦µÀ¾úµ÷½ÚµÄË¥ÀÏÏà¹Ø¼²²¡Ò©ÎïÑз¢ÌṩÁËʵÑéÒÀ¾Ý¡££¨ÉϺ£ÖÐÒ½Ò©´óÑ§ÍøÕ¾£©
? ÉϺ£ÖÐÒ½Ò©´óѧ£ºÖйúÖÐÒ½¿Ætaptapµãµã¹ÙÍøÈë¿ÚÓëÎÒУǩ¶©È˲ÅÅàÑøºÏ×÷ÐÒé
½üÈÕ£¬ÖйúÖÐÒ½¿Ætaptapµãµã¹ÙÍøÈë¿ÚÓëÉϺ£ÖÐÒ½Ò©´óѧÒÔ¹²½¨¡°ÖйúÖÐÒ½¿Ætaptapµãµã¹ÙÍøÈë¿Ú-ÉϺ£ÖÐÒ½Ò©´óѧÁªºÏtaptapµãµã¹ÙÍøÈë¿Ú¡±µÄÐÎʽ£¬Ì½Ë÷Ñо¿·ûºÏ¸ß²ã´ÎÖÐÒ½È˲ÅÅàÑøÌØµãºÍ°Î¼â´´ÐÂÈ˲ųɳ¤¹æÂɵĹÜÀíÖÆ¶È¡¢ÅäÌ×Õþ²ßºÍÅàÑøÄ£Ê½£¬²¢ÒÔ´ËΪÆðµã£¬È«Ãæ¼Óǿ˫·½ÔÚÖÐҽѧ½ÌÓý¡¢¿ÆÑС¢Ò½ÁƵĽ»Á÷ºÍÁªÏµ£¬ÊµÏÖǿǿÁªºÏ¡££¨ÉϺ£ÖÐÒ½Ò©´óÑ§ÍøÕ¾£©
?ÄϾ©´óѧ£ºÉúÃü¿ÆÑ§taptapµãµã¹ÙÍøÈë¿Ú¶ÀÚ¡¢Õžþ·åÍŶÓͨ¹ý½«Æ¢Ôà"ת»¯"Ϊ¸ÎÔàÖÎÁÆÖÕÄ©ÆÚ¸Î²¡
½üÈÕ£¬ÄϾ©´óѧÉúÃü¿ÆÑ§taptapµãµã¹ÙÍøÈë¿Ú£¬Ò½Ò©ÉúÎï¼¼Êõ¹ú¼ÒÖØµãʵÑéÊÒ¶ÀÚ½ÌÊÚ¡¢Õžþ·å½ÌÊںͰÄÃÅ´óѧÍõ´ºÃ÷½ÌÊÚÍŶӳ¢ÊÔÓÃÒ»ÖÖÆ÷¹ÙÏòÁíÒ»ÖÖÆ÷¹Ù"ת»¯"µÄ·½·¨£¬ÔÚÌåÄÚ½«Æ¢Ôàת»¯ÎªÓй¦ÄܵĸÎÔà¡£Ñо¿³É¹ûÒÔ" Transforming the Spleen into a Liver-like Organ in vivo"ΪÌâÓÚ2020Äê6ÔÂ10ÈÕÔÚScience AdvancesÉÏÔÚÏß·¢±í¡£¸ÃÑо¿±»ÈÏΪÊÇ×éÖ¯¹¤³ÌÁìÓòµÄÍ»ÆÆÐÔ½øÕ¹£¬Science ÔÓÖ¾ÔÚÆäÐÂýÌåÍÆ½éÖиøÓè±¾Ñо¿¸ß¶ÈÆÀ¼Û£¬ÈÏΪ¸Ã¼¼ÊõÊÇÔÙÉúҽѧÁìÓòÔÚÆ÷¹ÙÒÆÖ²ºÍ×éÖ¯¹¤³ÌÖ®ÍâµÄÒ»ÖÖȫеļ¼ÊõÑ¡Ôñ¡££¨ÄϾ©´óÑ§ÍøÕ¾£©
?ÄϾ©´óѧ£ºÄ£Ê½¶¯ÎïÑо¿Ëù¸ÊÕñ¼Ì½ÌÊÚ¿ÎÌâ×é½Òʾ¹Ç÷À¼¡ÏËÎ¬ÌØÐÔºÍÔ˶¯ÄÍÁ¦¾ö¶¨×îнøÕ¹
6ÔÂ16ÈÕ£¬ÄϾ©´óѧģʽ¶¯ÎïÑо¿Ëù¸ÊÕñ¼Ì½ÌÊÚʵÑéÊÒÔÚ¹ú¼ÊÖøÃûҽѧÆÚ¿¯Journal of Clinical InvestigationÔÚÏß·¢±íÁËÌâΪ¡°Histone methyltransferase MLL4 controls myofiber identity and muscle performance through MEF2 interaction¡±µÄÑо¿³É¹û¡£´ËÏ×÷½ÒʾÁ˹Ç÷À¼¡ÏËÎ¬ÌØÐÔºÍÔ˶¯ÄÍÁ¦¾ö¶¨Ð»úÖÆ£¬ÎªÔöÇ¿¼¡È⽡¿µÒÔ¶Ô¿¹¸÷ÖÖ´úлºÍ¼¡Èâ¼²²¡ÌṩÁËеÄÖÎÁÆ»ú»á¡££¨ÄϾ©´óÑ§ÍøÕ¾£©
?Õã½´óѧ£ºÑîΡ¡¢ÓàÅæÁØÍŶӽÒʾÄÉÃײÄÁÏÒý·¢·Î²¿Ñ×Ö¢·´Ó¦µÄ·Ö×Ó»úÖÆ
½üÈÕ£¬Õã½´óѧҽtaptapµãµã¹ÙÍøÈë¿ÚÑîΡ¡¢ÓàÅæÁØ¿ÎÌâ×éÔÚ¹ú¼ÊÖøÃû¶¾ÀíѧÆÚ¿¯Particle and Fibre ToxicologyÉÏ·¢±íÁËÌâΪSilica nanoparticles induce lung inflammation in mice via ROS/PARP/TRPM2 signaling-mediated lysosome impairment and autophagy dysfunctionµÄÑо¿ÂÛÎÄ£¬½ÒʾÁËÄÉÃ×¶þÑõ»¯¹è¿ÅÁ££¨silica nanoparticles£¬SiNPs£©Í¨¹ýROS/PARP-1/TRPM2ÐźÅͨ·Òý·¢·Î²¿Ñ×Ö¢µÄ·Ö×Ó»úÖÆ£¬Îª½ÒʾÄÉÃײÄÁϽ鵼µÄ·Î²¿ËðÉË»úÖÆÌṩÁËеÄÊӽǣ¬Í¬Ê±ÎªÄÉÃײÄÁÏÒý·¢µÄÑ×Ö¢ÐÔ¼²²¡µÄÔ¤·ÀºÍÖÎÁÆÌṩÁËеİе㡣Õã½´óÑ§ÍøÕ¾£¨ÉϺ£ÖÐÒ½Ò©´óÑ§ÍøÕ¾£©
?Õã½´óѧ£ºÓ¦ËÌÃô¡¢Éò»ªºÆ½ÌÊÚÍŶÓCell Research·¢ÎĽÒʾÖ×Áö»ùÒò×éÆÕͨ´àÐÔλµãÐòÁÐͼÆ×
½üÈÕ£¬Ó¦ËÌÃô¡¢Éò»ªºÆ½ÌÊÚÍŶÓÓëÈÕÄÚÍß´óѧThanos D. Halazonetis½ÌÊÚÍŶÓÔÚ¹ú¼ÊȨÍþѧÊõÆÚ¿¯Cell Research¡°±³¿¿±³¡±·¢±íÁËÌâΪGenome-wide High Resolution Mapping of Mitotic DNA Synthesis Sites and Common Fragile Sites by Direct SequencingµÄÑо¿ÂÛÎÄ£¬Ê״νÒʾÁËÆÕͨ´àÐÔλµãµÄÈ«»ùÒò×éÐòÁÐͼÆ×£¬ÎªÑо¿ÆäÉúÎïѧÒâÒåºÍÏà¹Ø¼²²¡ÖÎÁưеãÌṩÁËÖØÒªÒÀ¾Ý¡££¨Õã½´óѧ»ù´¡Ò½taptapµãµã¹ÙÍøÈë¿Ú£©
?Õã½´óѧ£ºÏĴ󾲡¢ÎâÒ»»ªÑо¿ÍŶӷ¢ÏÖ¿¹ÑªÐ¡°åÒ©ÎïÌæ¸ñÈðÂå¾ßÓÐÒÖÖÆNLRP3Ñ×֢СÌåµÄй¦ÄÜ
½üÈÕ£¬Õã½´óѧ¹«¹²ÎÀÉútaptapµãµã¹ÙÍøÈë¿Ú¡¢¸½Êô¸¾²ú¿ÆÒ½ÔºÏĴ󾲡¢ÎâÒ»»ªÑо¿ÍŶÓÔÚNature×Ó¿¯Cellular & Molecular Immunology (IF=8.213)ÔÚÏß·¢±íÑо¿ÂÛÎÄ¡°Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway¡±¡£¸ÃÑо¿´Óϸ°ûˮƽ¡¢Ð¡Êó¶¯ÎïÄ£ÐͺÍÁÙ´²Ñù±¾·ÖÎö±íÃ÷¿¹ÑªÐ¡°åÒ©ÎïÌæ¸ñÈðÂå¾ßÓÐÒÖÖÆNLRP3Ñ×֢СÌ弤»îµÄй¦ÄÜ£¬²¢²ûÃ÷ÁËÆä¿¹Ñ××÷Óò»ÒÀÀµÓÚ¿¹ÑªÐ¡°åÐźÅͨ·µÄлúÖÆ¡££¨Õã½´óÑ§ÍøÕ¾£©
?°²»ÕÒ½¿Æ´óѧ£ºÉñ¾¿ÆÑ§ÁìÓòÖøÃûÆÚ¿¯·¢±íÌÕÎľ긱½ÌÊÚÑо¿ÂÛÎÄ
½üÈÕ£¬°²»ÕÒ½¿Æ´óѧ»ù´¡Ò½taptapµãµã¹ÙÍøÈë¿ÚÌÕÎľ긱½ÌÊÚΪµÚÒ»×÷Õߣ¬Öйú¿ÆÑ§¼¼Êõ´óѧÉúÃü¿ÆÑ§Óëҽѧ²¿ÕÅÖǽÌÊÚΪͨѶ×÷ÕßµÄÑо¿ÂÛÎÄ¡¶MeCP2µ÷¿ØÂýÐÔÌÛÍ´µÄ´«´ú£¨MeCP2 mediates transgenerational transmission of chronic pain£©¡·£¬·¢±íÓÚÉñ¾¿ÆÑ§ÁìÓòȨÍþÆÚ¿¯¡¶Éñ¾ÉúÎïѧ½øÕ¹£¨Progress in Neurobiology£©¡·¡£¸ÃÑо¿´Ó¡°»ùÒò-·Ö×Ó-ϸ°û¡±¶à²ã´Îˮƽ½Òʾ±í¹ÛÒÅ´«»úÖÆµ÷½ÚÉñ¾»·Â·µÄ²»Á¼ÊÊÓ¦ÐÔ×îÖÕµ¼ÖÂÌÛÍ´³ÖÐøÐÔ£¬ÎªÀí½âÌÛÍ´µÄ³Ö¾ÃÐÔºÍÍç¹ÌÐÔÌṩÁËеÄÀíÂÛÒÀ¾Ý¡££¨°²»ÕÒ½¿Æ´óÑ§ÍøÕ¾£©
NO.3 ²úÒµ¶¯Ì¬
?ÉϺ£ÊУºÉϺ£½Ý˼Ӣ´ïÒ½Ò©¹«Ë¾Íê³É½üÒÚÔªA+ÂÖÈÚ×Ê
6ÔÂ15ÈÕ£¬ÉϺ£½Ý˼Ӣ´ïÒ½Ò©¹«Ë¾Ðû²¼Íê³É½üÒÚÔªÈËÃñ±ÒA+ÂÖÈÚ×Ê£¬±¾ÂÖÈÚ×ÊÓɾÛÃ÷´´Í¶ÁìͶ£¬Òзæ×ʱ¾¡¢¹ú·¢´´Í¶¡¢ÖµÀ×ʱ¾ºÍ¶«·½¸»º£¸úͶ¡£Ö÷ÒªÓÃÓÚÍÆ¶¯½Ý˼Ӣ´ïERK¼¤Ã¸ÒÖÖÆ¼ÁJSI-1187¿ªÕ¹IÆÚÁÙ´²ÊÔÑ飬ÒÔ¼°½¨Á¢ÒÔ¿¹Ö×ÁöÐÂҩΪºËÐĵÄÑз¢¹ÜÏß¡£½Ý˼Ӣ´ïλÓÚÉϺ£ÕŽ¿ÆÑ§³Ç¹ú¼ÊÒ½Ñ§Ô°Çø£¬×¨×¢ÓÚС·Ö×ÓÔ´´¿¹°©ÐÂÒ©µÄÑз¢¡££¨Í¶×ʽ磩
? ½ËÕÊ¡£ººãÈðÒ½Ò©ÈëÑ¡2020ÄêÈ«ÇòÖÆÒ©ÆóÒµTOP50°ñµ¥
6ÔÂ12ÈÕ£¬PharmExec£¨ÃÀ¹úÖÆÒ©¾ÀíÈËÔÓÖ¾£©¹«²¼ÁË2020ÄêÈ«ÇòÖÆÒ©ÆóÒµTOP50°ñµ¥¡£¸Ã°ñµ¥Ö÷ÒªÒÀ¾Ý¸÷¸öÆóÒµ2019²ÆÄê´¦·½Ò©ÏúÊÛÊÕÈë½øÐÐÅÅÃû£¬¸üÄÜ·´Ó³ÆóÒµÖÆÒ©ÒµÎñµÄÕûÌåʵÁ¦¡£ºãÈðÒ½Ò©ÅÅÃûµÚ43λ¡££¨ºãÈðÒ½Ò©ÍøÕ¾£©
? Õã½Ê¡£º³©ÏªÖÆÒ©Íê³É8000ÍòÔªBÂÖÈÚ×Ê
6ÔÂ15ÈÕ£¬º¼ÖÝÒ©³©ÏªÖÆÒ©Ðû²¼Íê³ÉÁË8000ǧÍòÈËÃñ±ÒBÂÖÈÚ×Ê¡£Í¶×Ê·½ÊÇһƷºìÒ©Òµ¡£´ËÂÖÈÚ×ÊÖ÷ÒªÊÇΪ¿ÆÑÐÏîÄ¿µÄÍÆ½ø£¬Ñо¿ÁÙ´²ÏîÄ¿£¬ÒÔ¼°¿ÆÑÐÍŶӵÄÀ©³äµÈ·½Ãæ¡£³©ÏªÖÆÒ©ÊÇÒ»¼ÒÒÔÎüÈë¸øÒ©¼¼ÊõΪºËÐĵĸ߿Ƽ¼¹«Ë¾¡£±¾¹«Ë¾×ÅÑÛÓÚÉúÎïÖÆÒ©Ñз¢ºÍÒ½ÁÆÆ÷еµÄ´´Ð£¬ÆäÖеĸɷÛÖÆ±¸ºÍ¸ßЧ±ã½ÝµÄÎüÈëÆ÷ÕâÁ½ÏîÖ÷Òª¼¼Êõ²úÆ·£¬»ñµÃÁ˹ú¼ÒµÄרÀû±£»¤¡££¨ÐÂÀ˲ƾ£©
? Õã½Ê¡£ºº¼Öݽ¡º£¿Æ¼¼»ñͶÊýǧÍò
6ÔÂ18ÈÕ£¬º¼Öݽ¡º£¿Æ¼¼ÓÐÏÞ¹«Ë¾Íê³ÉÊýǧÍòÔªA2ÂÖÈÚ×Ê£¬±¾ÂÖÈÚ×ÊÓɹè¹ÈÒøÐÐͶ×Ê£¬ÏĶû°Í×·¼ÓͶ×Ê£¬ÓÉ̽Õë×ʱ¾¹«Ë¾µ£ÈζÀ¼Ò²ÆÎñ¹ËÎÊ¡£±¾ÂÖÈÚ×ʽ«ÓÃÓÚר¿Æ¼²²¡¹ÜÀí·½Ïò²¼¾Ö£¬ÉîÍÚ´¹Ö±×¨¿Æ¼²²¡¹ÜÀíÁìÓò¡£½¡º£¿Æ¼¼³ÉÁ¢ÓÚ2015Ä꣬ÊǹúÄÚÊ׸öרעÓÚÔººóËæ·ÃÓ뻼Õß¹ÜÀíµÄ¹ú¼Ò¸ßм¼ÊõÆóÒµ¡££¨ËѺüÍø£©